ACR Meeting Abstracts

ACR Meeting Abstracts

  • Meeting Abstracts
    • All Meetings
    • PRSYM 2026
    • ACR Convergence 2025
    • Download Abstract Supplements
  • Keyword Index
  • Search
  • My Favorites
    • View and print all favorites
    • Clear all favorites

Abstract Number: 1882

30-Day Readmission Among Patients with Rheumatoid Arthritis and Their Independent Predictors: Insights from National Readmission Database

Shobhit Piplani1, Priyanshu Jain2, Vladimir Jelic3, Clement Tagoe4 and Beverly Johnson5, 1Jacobi Medical Center/North Central Bronx Albert Einstein College of Medicine NYC Health and Hospitals, Bronx, NY, 2Jawaharlal Nehru Medical College, Belgaum, Karnataka, India, Bronx, NY, 3Jacobi Medical Center/North Central Bronx, Bronx, NY, 4Albert Einstein College of Medicine, FRESH MEADOWS, NY, 5Albert Einstein College of Medicine, New York, NY

Meeting: ACR Convergence 2024

Keywords: Epidemiology, Health policy, Outcome measures, population studies, rheumatoid arthritis

  • Tweet
  • Email a link to a friend (Opens in new window) Email
  • Print (Opens in new window) Print
Session Information

Date: Monday, November 18, 2024

Title: Epidemiology & Public Health Poster III

Session Type: Poster Session C

Session Time: 10:30AM-12:30PM

Background/Purpose: Rheumatoid Arthirits (RA) is associated with heightened morbidity, diminished quality of life, and increased healthcare expenses. This research aims to bridge this gap by conducting a comprehensive examination of 30-day readmissions in RA patients, seeking to uncover independent predictors, determine the principal factors contributing to these readmissions and offer insights for targeted interventions to improve healthcare quality in a nationally representative sample of RA patients.

Methods: In this retrospective investigation, the 2019 data from Nationwide Readmission Database were utilized. The primary focus was on determining the rate of readmission for all causes within 30 days post-discharge. Secondary objectives included assessing hospital-level metrics. The identification of independent risk factors for readmission was carried out through Cox regression analysis.

Results: The study examined 7,806 index admissions of RA patients, identifying 90 readmissions. The majority were female (69.15% index, 76.61% readmissions). Medicare covered 58.76% of index cases, decreasing to 40.81% in readmissions. Notably, 35.48% of index and 24.87% of readmitted patients were smokers. Large hospitals (56.22% index, 65.41% readmissions) in metropolitan areas (60.4% index, 63.09% readmissions) were predominant. The most common co-morbidities included hypertension (60.01% index, 55.61% readmissions), osteoarthritis (25.20% index, 15.97% readmissions), and chronic prednisone use (13.91% index, 33.72% readmissions). Most common diagnosis in RA patients’ readmissions included highlighted unspecified RA (M06.9) and Adult-Onset Still’s Disease (M06.1). Age demonstrated a significant inverse association (Adjusted Odds Ratio: 0.96, p< 0.001), while females exhibited a non-significant increase (1.52, p=0.215). Medicaid-insured patients had higher odds (2.77, p< 0.004), but no significant associations were observed for other insurance types. Various co-morbidities, such as Congestive Heart Failure (CHF), showed potential significance (0.036, p=0.097).  Notably, alcohol consumption (4.5, p< 0.0001) and liver conditions (4.09, p< 0.05) emerged as strong positive predictors.

Conclusion: In this nationally representative study, the most substantial risk factors for 30-day readmission in RA patients were female gender, younger age, public insurance, and higher comorbidity scores. Understanding these demographics and co-morbidities is crucial for developing targeted interventions to reduce RA re-admissions. The study recommends early diagnosis, regular monitoring, multidisciplinary care, patient education, and clinical guidelines to reduce readmissions and improve RA patient outcomes.


Disclosures: S. Piplani: None; P. Jain: None; V. Jelic: None; C. Tagoe: None; B. Johnson: Bristol-Myers Squibb(BMS), 5, Genentech, 5, GlaxoSmithKlein(GSK), 5, Janssen, 1, 2, 5, 11, UCB, 2.

To cite this abstract in AMA style:

Piplani S, Jain P, Jelic V, Tagoe C, Johnson B. 30-Day Readmission Among Patients with Rheumatoid Arthritis and Their Independent Predictors: Insights from National Readmission Database [abstract]. Arthritis Rheumatol. 2024; 76 (suppl 9). https://acrabstracts.org/abstract/30-day-readmission-among-patients-with-rheumatoid-arthritis-and-their-independent-predictors-insights-from-national-readmission-database/. Accessed .
  • Tweet
  • Email a link to a friend (Opens in new window) Email
  • Print (Opens in new window) Print

« Back to ACR Convergence 2024

ACR Meeting Abstracts - https://acrabstracts.org/abstract/30-day-readmission-among-patients-with-rheumatoid-arthritis-and-their-independent-predictors-insights-from-national-readmission-database/

Advanced Search

My Favorites

Save and print abstracts during your browser session by clicking the “Favorite” button at the bottom of any abstract (must have cookies enabled in browser). See saved favorites.

Abstract Policies

  • ACR Convergence Abstract Embargo Policies
  • ACR Convergence Abstract Permissions & Reprints
  • PRSYM Abstract Policies

ACR Convergence. Where Rheumatology Meets

ACR Convergence 2026

Join us November 6-11 in Orlando, Florida.
See Registration Information

  • Contact ACR
  • Privacy Policy
  • ACR Policies
  • Cookie Preferences

© Copyright 2026 American College of Rheumatology